Everolimus for Advanced Pancreatic Neuroendocrine Tumors

BACKGROUND: Everolimus, an oral inhibitor of mammalian target of rapamycin (mTOR), has shown antitumor activity in patients with advanced pancreatic neuroendocrine tumors, in two phase 2 studies. We evaluated the agent in a prospective, randomized, phase 3 study. METHODS: We randomly assigned 410 pa...

Full description

Saved in:
Bibliographic Details
Main Authors: Yao, James C., Shah, Manisha H., Ito, Tetsuhide, Bohas, Catherine Lombard, Wolin, Edward M., Van Cutsem, Eric, Hobday, Timothy J., Okusaka, Takuji, Capdevila, Jaume, de Vries, Elisabeth G.E., Tomassetti, Paola, Pavel, Marianne E., Hoosen, Sakina, Haas, Tomas, Lincy, Jeremie, Lebwohl, David, Öberg, Kjell
Format: Artigo
Language:Inglês
Published: 2011
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4208619/
https://ncbi.nlm.nih.gov/pubmed/21306238
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1009290
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items